• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰头十二指肠腺癌孤立局部和转移性复发的切除术。

Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma.

机构信息

Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA.

出版信息

HPB (Oxford). 2014 Mar;16(3):197-203. doi: 10.1111/hpb.12119. Epub 2013 Apr 22.

DOI:10.1111/hpb.12119
PMID:23601033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3945844/
Abstract

BACKGROUND

The majority of patients with periampullary cancer develop local or metastatic recurrence despite successful negative margin resection. Unfortunately, there are no established therapeutic strategies for managing these patients. The literature on the surgical resection of recurrent disease is limited.

METHODS

This is a retrospective study evaluating patients who underwent reoperative resection of recurrent periampullary cancer at a single institution between 1990 and 2011. Perioperative outcomes were compared with those of the original primary resections for patients with local recurrence. Kaplan-Meier curves were used to evaluate survival.

RESULTS

Twenty-two patients underwent reoperative resection following the successful primary resection of periampullary cancers. Median survival from the time of reoperation was 28.1 months. A greater survival benefit was seen in patients undergoing reoperative resection with >15 months between the primary resection and recurrence (40.6 months versus 8.2 months; P < 0.05). Complication rates were lower after reoperative resection compared with the primary resection (20% versus 70%). Perioperative characteristics including operative time, estimated blood loss and hospital stay were similar in both the primary and reoperation procedures.

CONCLUSIONS

Surgical resection of periampullary cancer recurrence is feasible, safe and may offer survival benefits in comparison with alternative treatment modalities. Reoperative resection should be considered, especially in patients in whom the time to recurrence is lengthy.

摘要

背景

尽管成功进行了阴性切缘切除,但大多数壶腹周围癌患者仍会出现局部或远处转移复发。遗憾的是,目前尚无针对这些患者的既定治疗策略。有关复发性疾病的外科切除的文献有限。

方法

这是一项回顾性研究,评估了 1990 年至 2011 年间在一家机构接受复发性壶腹周围癌再次手术切除的患者。将局部复发患者的围手术期结局与原始初次手术切除进行了比较。使用 Kaplan-Meier 曲线评估生存情况。

结果

22 例患者在成功进行壶腹周围癌初次切除后接受了再次手术切除。自再次手术时起的中位生存时间为 28.1 个月。在初次切除与复发之间间隔>15 个月的患者中,再次手术切除的生存获益更大(40.6 个月与 8.2 个月;P<0.05)。与初次切除术相比,再次手术切除后的并发症发生率更低(20%比 70%)。初次手术和再次手术的围手术期特征(包括手术时间、估计失血量和住院时间)相似。

结论

与其他治疗方式相比,手术切除壶腹周围癌复发是可行、安全的,并且可能带来生存获益。应考虑再次手术切除,特别是在复发时间较长的患者中。

相似文献

1
Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma.胰头十二指肠腺癌孤立局部和转移性复发的切除术。
HPB (Oxford). 2014 Mar;16(3):197-203. doi: 10.1111/hpb.12119. Epub 2013 Apr 22.
2
Reexploration for periampullary carcinoma: resectability, perioperative results, pathology, and long-term outcome.壶腹周围癌再次探查:可切除性、围手术期结果、病理学及长期预后
Ann Surg. 1999 Mar;229(3):393-400. doi: 10.1097/00000658-199903000-00013.
3
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection.胰脏切除术后局部复发性或转移性胰脏导管腺癌的选择性再手术。
J Gastrointest Surg. 2012 Sep;16(9):1696-704. doi: 10.1007/s11605-012-1912-8. Epub 2012 May 30.
4
Selective reoperation after primary resection as a feasible and safe treatment strategy for recurrent pancreatic cancer.初次切除术后选择性再次手术作为复发性胰腺癌可行且安全的治疗策略。
Medicine (Baltimore). 2016 Jul;95(30):e4191. doi: 10.1097/MD.0000000000004191.
5
Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival.再次手术切除孤立性局部复发性胰腺癌是可行的、安全的,且与令人鼓舞的生存结果相关。
Ann Surg Oncol. 2013 Mar;20(3):964-72. doi: 10.1245/s10434-012-2762-z. Epub 2012 Dec 12.
6
Reoperative surgery for periampullary adenocarcinoma.壶腹周围腺癌的再次手术
Arch Surg. 1991 Oct;126(10):1205-10; discussion 1210-2. doi: 10.1001/archsurg.1991.01410340043007.
7
Reoperative pancreaticoduodenectomy for periampullary carcinoma.壶腹周围癌的再次胰十二指肠切除术
ANZ J Surg. 2005 Jul;75(7):520-3. doi: 10.1111/j.1445-2197.2005.03438.x.
8
Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality.胰十二指肠切除术联合或不联合远端胃切除术及扩大腹膜后淋巴结清扫术治疗壶腹周围腺癌,第2部分:评估生存、发病率和死亡率的随机对照试验
Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8. doi: 10.1097/00000658-200209000-00012.
9
Periampullary adenocarcinoma: analysis of 5-year survivors.壶腹周围腺癌:5年生存者分析
Ann Surg. 1998 Jun;227(6):821-31. doi: 10.1097/00000658-199806000-00005.
10
Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.胰腺癌寡转移肺转移患者:手术切除的安全性和结果。
Surg Oncol. 2019 Dec;31:16-21. doi: 10.1016/j.suronc.2019.08.010. Epub 2019 Aug 26.

引用本文的文献

1
Meta-analysis of pancreatic re-resection for locally recurrent pancreatic cancer following index pancreatectomy.胰腺根治性切除术后局部复发性胰腺癌再次手术的Meta分析。
Ann Hepatobiliary Pancreat Surg. 2024 Aug 31;28(3):315-324. doi: 10.14701/ahbps.24-041. Epub 2024 May 28.
2
Surgical Resection or Ablation for Recurrent Pancreatic Ductal Adenocarcinoma: An Analysis of Oncologic Outcomes According to the Recurrence Type.复发性胰腺导管腺癌的手术切除或消融:根据复发类型的肿瘤学结局分析
Ann Surg Open. 2021 Sep 9;2(3):e096. doi: 10.1097/AS9.0000000000000096. eCollection 2021 Sep.
3
Stereotactic body radiation therapy for the treatment of locally recurrent pancreatic cancer after surgical resection.立体定向体部放射治疗用于治疗手术切除后局部复发的胰腺癌。
J Gastrointest Oncol. 2022 Jun;13(3):1402-1412. doi: 10.21037/jgo-22-38.
4
Resection of Recurrent Pancreatic Cancer: Who Can Benefit?复发性胰腺癌的切除术:谁能从中获益?
Visc Med. 2022 Feb;38(1):42-48. doi: 10.1159/000519754. Epub 2021 Nov 11.
5
Predicting early recurrence for resected pancreatic ductal adenocarcinoma: a multicenter retrospective study in China.预测切除术后胰腺导管腺癌的早期复发:一项中国多中心回顾性研究
Am J Cancer Res. 2021 Jun 15;11(6):3055-3069. eCollection 2021.
6
Value of regular endosonography and [18F]fluorodeoxyglucose PET-CT after surgery for gastro-oesophageal junction, stomach or pancreatic cancer.胃食管结合部、胃或胰腺癌手术后定期行内镜超声检查和 [18F]氟脱氧葡萄糖 PET-CT 的价值。
BJS Open. 2021 Mar 5;5(2). doi: 10.1093/bjsopen/zraa028.
7
Repeated Pancreatectomy for Isolated Local Recurrence in the Remnant Pancreas Following Radical Pancreatectomy for Pancreatic Ductal Adenocarcinoma: A Pooled Analysis.胰十二指肠切除术治疗胰腺导管腺癌后残胰孤立性局部复发的重复胰腺切除术:一项汇总分析
J Clin Med. 2020 Dec 5;9(12):3945. doi: 10.3390/jcm9123945.
8
Surgery for Recurrent Pancreatic Cancer: Is It Effective?复发性胰腺癌手术:是否有效?
Cancers (Basel). 2019 Jul 16;11(7):991. doi: 10.3390/cancers11070991.
9
Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma.定义和预测 957 例接受胰腺导管腺癌切除患者的早期复发。
Ann Surg. 2019 Jun;269(6):1154-1162. doi: 10.1097/SLA.0000000000002734.
10
Clinical implication of surgical resection for recurrent biliary tract cancer: Does it work or not?复发性胆管癌手术切除的临床意义:其是否有效?
Ann Gastroenterol Surg. 2017 Sep 14;1(3):164-170. doi: 10.1002/ags3.12036. eCollection 2017 Sep.

本文引用的文献

1
Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection.胰脏切除术后局部复发性或转移性胰脏导管腺癌的选择性再手术。
J Gastrointest Surg. 2012 Sep;16(9):1696-704. doi: 10.1007/s11605-012-1912-8. Epub 2012 May 30.
2
Cancer statistics, 2012.癌症统计数据,2012 年。
CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29. doi: 10.3322/caac.20138. Epub 2012 Jan 4.
3
[Re-resection for local recurrence in the remnant pancreas after pancreaticoduodenectomy for pancreatic cancer- a case report].[胰腺癌胰十二指肠切除术后残胰局部复发再次手术切除——1例病例报告]
Gan To Kagaku Ryoho. 2011 Nov;38(12):2448-50.
4
[Chemotherapy of metastatic pancreatic adenocarcinoma: challenges and encouraging results].[转移性胰腺腺癌的化疗:挑战与鼓舞人心的结果]
Bull Cancer. 2011 Dec;98(12):1439-46. doi: 10.1684/bdc.2011.1494.
5
FOLFIRINOX: a great leap forward, but for whom?FOLFIRINOX方案:向前的一大步,但对谁而言?
J Clin Oncol. 2012 Jan 1;30(1):114-5; author reply 114. doi: 10.1200/JCO.2011.39.4056. Epub 2011 Nov 28.
6
Successful resection of pancreatic carcinoma recurrence in the remnant pancreas after a pancreaticoduodenectomy.胰十二指肠切除术后残留胰腺中胰腺癌复发的成功切除
Hepatogastroenterology. 2011 Jul-Aug;58(109):1406-8. doi: 10.5754/hge09366.
7
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.5-氟尿嘧啶/亚叶酸钙联合伊立替康和奥沙利铂(FOLFIRINOX)作为转移性胰腺腺癌二线化疗。
Oncology. 2011;80(5-6):301-6. doi: 10.1159/000329803. Epub 2011 Jul 18.
8
Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival.孤立性胰腺腺癌转移行肺切除术:结局和生存分析。
J Gastrointest Surg. 2011 Sep;15(9):1611-7. doi: 10.1007/s11605-011-1605-8. Epub 2011 Jul 2.
9
Local recurrence of pancreatic cancer after primary surgical intervention: how to deal with this devastating scenario?原发性手术干预后胰腺癌的局部复发:如何应对这种毁灭性的情况?
Surg Oncol. 2011 Dec;20(4):e133-42. doi: 10.1016/j.suronc.2011.04.004. Epub 2011 May 14.
10
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.FOLFIRINOX 对比吉西他滨治疗转移性胰腺癌。
N Engl J Med. 2011 May 12;364(19):1817-25. doi: 10.1056/NEJMoa1011923.